RelB Recombinant Rabbit Monoclonal Antibody [SD07-39]

About this product

In resting cells, RelB is sequestered by the NF-κB precursor protein p100 in the cytoplasm. A select set of TNF-R superfamily members, including lymphotoxin β-receptor (LTβR), BAFF-R, CD40 and RANK, activate the non-canonical NF-κB pathway. In this pathway, NIK stimulates the processing of p100 into p52, which in association with RelB appears in the nucleus as RelB:p52 NF-κB heterodimers. RelB:p52 activates the expression homeostatic lymphokines,which instruct lymphoid organogenesis and determine the trafficking of naive lymphocytes in the secondary lymphoid organs. Recent studies has suggested that the functional non-canonical NF-κB pathway is modulated by canonical NF-κB signalling. For example, syntheses of the constituents of the non-canonical pathway, viz RelB and p52, are controlled by canonical IKK2-IκB-RelA:p50 signalling.Moreover, generation of canonical and non-canonical dimers, viz RelA:p50 and RelB:p52, within the cellular milieu are mechanistically interlinked. These analyses suggest that an integrated NF-κB system network underlies activation of both RelA and RelB containing dimer and that a malfunctioning canonical pathway will lead to an aberrant cellular response also through the non-canonical pathway. Most intriguingly, a recent study identified that TNF-induced canonical signalling subverts non-canonical RelB:p52 activity in the inflamed lymphoid tissues limiting lymphocyte ingress.Mechanistically, TNF inactivated NIK in LTβR‐stimulated cells and induced the synthesis of Nfkb2 mRNA encoding p100; these together potently accumulated unprocessed p100, which attenuated the RelB activity. A role of p100/Nfkb2 in dictating lymphocyte ingress in the inflamed lymphoid tissue may have broad physiological implications.

Specifications

Catalog number

ET1612-18

Size / count

100 µL

Dry ice

No

Hazardous

No

Discontinued

No

CAS Number

9000-83-3

Product Name Alternative

I REL antibody I-Rel antibody IREL antibody Nuclear factor of kappa light polypeptide gene enhancer in B cells 3 antibody relB antibody RELB_HUMAN antibody Reticuloendotheliosis viral oncogene homolog B antibody Transcription factor Rel B antibody Transcription factor RelB antibody v rel avian reticuloendotheliosis viral oncogene homolog B antibody v rel reticuloendotheliosis viral oncogene homolog B antibody

Abbreviation

RELB

Swiss Prot

Q01201 Human

Cellular Locus

Nucleus, Cytoplasm, cytoskeleton, microtubule organizing center, centrosome.

Host

Rabbit

Species Reactivity

Human

Immunogen

Synthetic peptide within Human RelB aa 1-50 / 579.

Isotype

IgG

Conjugation

Non-conjugated

Type

Recombinant Rabbit monoclonal Antibody

Applications

WB, IF-Tissue, IHC-P, IP

Positive Control

Raji cell lysate, Daudi cell lysate, human tonsil tissue.

Concentration

1 mg/mL

Dilution

WB: 1:1,000 ;IF-Tissue: 1:50-1:200 ;IHC-P: 1:50-1:200 ;IP: Use at an assay dependent concentration.

Purity

Protein A affinity purified.

Form

Liquid

Buffer

1*TBS (pH7.4), 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Molecular Weight

Predicted band size: 62 kDa

Storage Conditions

Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Recombinant Antibody

Yes